CHICAGO and FORT WORTH, Texas — September 10, 2025 — Leads & Copy — Actuate Therapeutics, Inc. (NASDAQ: ACTU) has announced the pricing of an underwritten public offering of 2,142,858 shares of its common stock at $7.00 per share. The clinical-stage biopharmaceutical company, which focuses on developing therapies for high-impact, difficult-to-treat cancers, has also granted underwriters a 30-day option to purchase up to 321,428 additional shares.
The offering is expected to close on September 11, 2025, pending customary closing conditions. Lucid Capital Markets is the sole book-running manager, and Titan Partners Group is acting as financial advisor.
The company anticipates gross proceeds of approximately $15.0 million, which will be used for working capital and general corporate purposes.
The offering is made under a shelf registration statement on Form S-3, previously filed with the SEC. The final prospectus supplement will be available on the SEC’s website and from Lucid Capital Markets, LLC.
Investor Contact:
Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
Source: Actuate Therapeutics, Inc.
